Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;24(1):562.
doi: 10.1186/s12913-024-11001-3.

A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list

Shi-Yi Bao  1 , Liu Liu  1 , Fu-Ming Li  1 , Yi Yang  1 , Yan Wei  1 , Hui Shao  2 , Jian Ming  1 , Jun-Tao Yan  1 , Ying-Yao Chen  3
Affiliations

A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list

Shi-Yi Bao et al. BMC Health Serv Res. .

Abstract

Background: This study aimed to examine the reporting quality of existing economic evaluations for negotiated glucose-lowering drugs (GLDs) included in China National Reimbursement Drug List (NRDL) using the Consolidated Health Economic Evaluation Reporting Standards 2013 (CHEERS 2013).

Methods: We performed a systematic literature research through 7 databases to identify published economic evaluations for GLDs included in the China NRDL up to March 2021. Reporting quality of identified studies was assessed by two independent reviewers based on the CHEERS checklist. The Kruskal-Wallis test and Mann-Whitney U test were performed to examine the association between reporting quality and characteristics of the identified studies.

Results: We have identified 24 studies, which evaluated six GLDs types. The average score rate of the included studies was 77.41% (SD:13.23%, Range 47.62%-91.67%). Among all the required reporting items, characterizing heterogeneity (score rate = 4.17%) was the least satisfied item. Among six parts of CHEERS, results part scored least at 0.55 (score rate = 54.79%) because of the incompleteness of characterizing uncertainty. Results from the Kruskal-Wallis test and Mann-Whitney U test showed that model choice, journal type, type of economic evaluations, and study perspective were associated with the reporting quality of the studies.

Conclusions: There remains room to improve the reporting quality of economic evaluations for GLDs in NRDL. Checklists such as CHEERS should be widely used to improve the reporting quality of economic researches in China.

Keywords: Economic evaluations; Glucose-lowering drugs; National Reimbursement Drug List (NRDL); Quality evaluation; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA 2020 flow diagram of literature review and screening
Fig. 2
Fig. 2
The reporting results of each appraised article based on the CHEERS checklist items
Fig. 3
Fig. 3
Overview of evaluation using CHEERS criteria, per article and per item. A Ranking of completeness of the 24-item CHEERS evaluation applied on the 24 selected studies. B Ranking of completeness of subitems
Fig. 4
Fig. 4
The proportion of studies that satisfy each major parts are detailed according to overall CHEERS instrument
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Wang Q, Zhang X, Fang L, Guan Q, Guan L, Li Q. Prevalence, awareness, treatment and control of diabetes mellitus among middle-aged and elderly people in a rural Chinese population: a cross-sectional study. Plos One. 2018;13(6):e0198343. doi: 10.1371/journal.pone.0198343. - DOI - PMC - PubMed
    1. Ma RCW. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 2018;61(6):1249–1260. doi: 10.1007/s00125-018-4557-7. - DOI - PubMed
    1. Tang M, Song P, He J. Progress on drug pricing negotiations in China. Biosci Trends. 2020;13(6):464–468. doi: 10.5582/bst.2019.01339. - DOI - PubMed
    1. Brain D, Jadambaa A. Economic evaluation of long-term survivorship care for cancer patients in OECD Countries: a systematic review for decision-makers. Int J Environ Res Public Health. 2021;18(21):11558. doi: 10.3390/ijerph182111558. - DOI - PMC - PubMed

Publication types

Substances